Advertisement

Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia

  • Patrick A. Stolz
  • Heidi J. WehringEmail author
  • Fang Liu
  • Raymond C. Love
  • Marcus Ellis
  • Bethany A. DiPaula
  • Deanna L. Kelly
Original Paper
  • 27 Downloads

Abstract

To estimate 20-year mortality risk in people with schizophrenia treated with second-generation antipsychotics (SGA) and examine the effects of cigarette smoking on mortality. Of the 1199 individuals with schizophrenia in the study, estimated 20-year all-cause mortality risk by Kaplan Meier Curve was 30% and leading causes of death included 27% cardiovascular disease, 13% cancer, 12% non-HIV infection, 5% respiratory causes, 20% other causes and 18% had unknown cause of death. For all-cause mortality, we found that white race and male sex were significant risk factors (HR = 1.5, p = 0.002 and HR = 1.33, p = 0.033, respectively). For cardiovascular mortality risk, we showed that cigarette smokers and white race were at higher risk (HR = 1.86, p = 0.017 and HR = 1.71, p = 0.045, respectively). Cardiovascular mortality risk at 20-years is 11%. Kaplan-Meier Survival Curve showed a statistical difference for smokers and non-smokers in cardiovascular mortality over the 20-year follow-up (Log rank chi-square = 5.35, df = 1, p = 0.02). 20-year all-cause mortality risk for individuals with schizophrenia was found to be 30% with cardiovascular disease as a leading cause. Cigarette smokers and white race were associated with an increased risk of death. Regarding cardiovascular mortality specifically, cigarette smoking increased risk by 86% over a 20-year period. Clozapine was neither a risk factor for all-neither cause nor cardiovascular mortality. This data suggests that long-term cardiovascular mortality continues to be increased in schizophrenia for those who are or have been cigarette smokers.

Keywords

Schizophrenia Mortality Clozapine Cigarette Smoking Cardiovascular 

Notes

Acknowledgments

We would like to thank and acknowledge those who helped create the database and have worked on this project historically. We thank Robert R Conley, Kristen Mackowick, and Robert P. McMahon.

Funding

This study was funded in part by National Institute of Mental Health R01(MH102215) (Kelly, PI) and by National Institute on Drug Abuse K23(DA034034-01A1) (Wehring, PI).

Compliance with Ethical Standards

Conflict of Interest

Deanna L. Kelly: Advisory board for Lundbeck and a consultant for HLS Therapeutics.

Raymond C. Love: Speaking fee for Nevada Psychiatric Association, received honorarium for Advisory Board on Pharmacist Administration of Medication, and is part of the National Alliance of State Pharmacy Association.

All other authors declare they have no conflicts of interest.

Ethical Approval

All procedures performed were done so in accordance with the ethical standards of the University of Maryland and Maryland Department of Health Institutional Review Boards and with the 1964 Helsinki declaration and its later amendments.

Informed Consent

A waiver of informed consent was approved by the University of Maryland-Baltimore and the Maryland Department of Health Institutional Review Boards for this retrospective study.

References

  1. 1.
    Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58(8):668–76.CrossRefGoogle Scholar
  2. 2.
    Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–59.CrossRefGoogle Scholar
  3. 3.
    Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiat. 2015;72(12):1172–81.CrossRefGoogle Scholar
  4. 4.
    Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry. 1997;171(6):502–8.CrossRefGoogle Scholar
  5. 5.
    Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–21.CrossRefGoogle Scholar
  6. 6.
    Diderichsen F, Andersen I, Manuel C, Health WGotDRoSDo, Andersen A-MN, Bach E, et al. Health Inequality-determinants and policies. Scand J Public Health. 2012;40(8_suppl):12–105.CrossRefGoogle Scholar
  7. 7.
    Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83–8.CrossRefGoogle Scholar
  8. 8.
    Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–48.CrossRefGoogle Scholar
  9. 9.
    Lawrence D, Kisely S, Pais J. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry. 2010;55(12):752–60.CrossRefGoogle Scholar
  10. 10.
    Mitchell AJ, Lawrence D. Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. Br J Psychiatry. 2011;198(6):434–41.CrossRefGoogle Scholar
  11. 11.
    Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M, Group IS. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet. 2009;373(9661):408–15.CrossRefGoogle Scholar
  12. 12.
    Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007.Google Scholar
  13. 13.
    Catts V, Catts S, O’toole B, Frost A. Cancer incidence in patients with schizophrenia and their first-degree relatives–a meta-analysis. Acta Psychiatr Scand. 2008;117(5):323–36.CrossRefGoogle Scholar
  14. 14.
    Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatr. 1998;155(11):1490–501.CrossRefGoogle Scholar
  15. 15.
    Kelly DL, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Boggs DL, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull. 2011;37:832–8.  https://doi.org/10.1093/schbul/sbp152.CrossRefPubMedGoogle Scholar
  16. 16.
    Moeller-Saxone K. Cigarette smoking and interest in quitting among consumers at a psychiatric disability rehabilitation and support Service in Victoria. Aust N Z J Public Health. 2008;32(5):479–81.  https://doi.org/10.1111/j.1753-6405.2008.00283.x.CrossRefPubMedGoogle Scholar
  17. 17.
    Cox DR. Regression models and life-tables. J R Stat Soc Ser B Methodological. 1972;34(2):187–220.Google Scholar
  18. 18.
    de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry. 1995;152(3):453–5.CrossRefGoogle Scholar
  19. 19.
    Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183–94 quiz 47, 273–4.CrossRefGoogle Scholar
  20. 20.
    Murphy SL, Xu J, Kochanek KD, Curtin SC, Arias E. Deaths: final data for 2015. 2017.Google Scholar
  21. 21.
    Hatsukami DK, Henningfield JE, Kotlyar M. Harm reduction approaches to reducing tobacco-related mortality. Annu Rev Public Health. 2004;25:377–95.CrossRefGoogle Scholar
  22. 22.
    Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;1.  https://doi.org/10.1002/14651858.CD000059.pub2.
  23. 23.
    Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101(3):277–88.CrossRefGoogle Scholar
  24. 24.
    Hayes RD, Downs J, Chang C-K, Jackson RG, Shetty H, Broadbent M, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2014;41(3):644–55.CrossRefGoogle Scholar
  25. 25.
    Kelly DL, McMahon RP, Liu F, Love RC, Wehring H, Shim JC, et al. Cardiovascular disease mortality in chronic schizophrenia patients treated with clozapine. J Clin Psychiatry. 2010;71(3):304–11.CrossRefGoogle Scholar
  26. 26.
    Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–7.CrossRefGoogle Scholar
  27. 27.
    Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8(6):671–7.CrossRefGoogle Scholar
  28. 28.
    Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325(7372):1070.CrossRefGoogle Scholar
  29. 29.
    Gelijns AC. Modern methods of clinical investigation: National Academies Press; 1990.Google Scholar
  30. 30.
    Staffa JA, Jones JK, Gable CB, Verspeelt JP, Amery WK. Risk of selected serious cardiac events among new users of antihistamines. Clin Ther. 1995;17(6):1062–77.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.University of Maryland School of PharmacyBaltimoreUSA
  2. 2.Maryland Psychiatric Research CenterUniversity of Maryland Baltimore School of MedicineCatonsvilleUSA

Personalised recommendations